A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)
Status:
Not yet recruiting
Trial end date:
2022-09-28
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of
belzutifan (MK-6482) following a single oral 120 mg dose in participants with end stage renal
disease (ESRD) before and after hemodialysis (HD) to each other and also to that of healthy
matched control participants. This study will also evaluate the safety and tolerability of a
single oral 120 mg dose of belzutifan in participants with ESRD and the extent of belzutifan
removed by HD.